Browse All

Current Filters

CLEAR FILTER x

TITLE

Effects of Oral Valiltramiprosate on Clinical Efficacy, Safety, and Brain Volume Outcomes in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD): Topline Results of the 78-week Phase 3 APOLLOE4 Trial

Biomarker-positive APOE4 Carriers with MCI Show Cognitive Stability over 4 Years of Oral Valiltramiprosate/ALZ-801 Treatment: MMSE Responder Analysis from the ALZ-801 Phase 2 Long-term Extension Study

Correlations between Clinical and Brain Volume Effects of Oral Valiltramiprosate in APOE4/4 Homozygotes with MCI: Pre-specified Analyses of the Phase-3 APOLLOE4 78-Week Trial in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD)

Clinical Effects of Oral Valiltramiprosate Treatment in APOE4 Carriers with Mild Cognitive Impairment (MCI): Results of the Phase 2 Study Long-term Extension over 3 Years